Register Login

VIVANI MEDICAL, INC. (VANI)

(10% Negative) VIVANI MEDICAL, INC. (VANI) Announces Delay in Implant Trials for a miniature Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot June 30, 2026, 5:38 p.m.

    📋 VIVANI MEDICAL, INC. (VANI) - Clinical Trial Update

    Filing Date: 2026-06-30

    Accepted: 2026-06-30 08:03:55

    Event Type: Clinical Trial Update

    Event Details:

    VIVANI MEDICAL, INC. (VANI) Announces Clinical Trial Update VIVANI MEDICAL, INC. (VANI) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Implant, conducted
    • Diseases/Conditions: a miniature, SLIM-2 which
    • Clinical Stage: Clinical Trial, Phase 1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Vivani

    🔬 Clinical Development Pipeline (VIVANI MEDICAL, INC.):

    Product Type Development Stage Therapeutic Area Source
    Exenatide Implant Other Phase PHASE1 Overweight and Obesity ClinicalTrials.gov
    Semaglutide Implant (NPM-139) Other Phase PHASE1 Obesity & Overweight ClinicalTrials.gov
    Semaglutide (Wegovy) weekly injection Other Phase PHASE1 Obesity & Overweight ClinicalTrials.gov
    Semaglutide, 1.0 mg/mL Other Phase PHASE1 Overweight and Obesity ClinicalTrials.gov
    Bydureon BCise (exenatide extended release) Other Phase PHASE1 Overweight and Obesity ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: VIVANI MEDICAL, INC.
    • Ticker Symbol: VANI

Search

News categories